Mgc Pharmaceuticals Share Discussion Threads

[flc] 12/5/2022 05:44

Hi Heat, all good cheers. Capita is on my watch list but I've not taken any. I'm currently out of MXC but will be back in shortly.

[looneytune] 11/5/2022 19:10

Listen to no one especially the pig hiding behind a Silly Billy handle. Pathetic twisted low life.
MGC is NOT going into administration.
Simply wait, watch & see! Not recommending anyone buy or sell simply watch.

[silly billy] 11/5/2022 18:48

I hope it did not hurt too much. You know you should never mess with the crew; we shorted 10m shs on that 200% spike.

Listen to billy.

This pig MXC is going to administration; I have marked yellow teeth for the kill. Need to learn to respect the KING.

[silly billy] 11/5/2022 18:46

superhero flc, how's the 100% loss on mcls. careful another 100% loss is coming here.

[sloppyjoe2] 11/5/2022 17:38

WTF is going to stop this constant drip-drip-drip decline?

[heatseek77] 11/5/2022 16:41

Wow I think our keyboard warrior got no Annie's...claiming a victory with a .025p drop 🤣😂🤣🤣

[heatseek77] 11/5/2022 16:39

billy no mates you on your own again keyboard girly, hows ya bedsit? X

[silly billy] 11/5/2022 15:48

Oh my gawh

when will the selling stop?

well well, it won't till we get our 0.05p target price.

[heatseek77] 10/5/2022 22:01

I think that silly can't even read, clearly CVC interested in CPI at 32p so may be worth a punt for me soon..

Heatseek77
8 May '22 - 09:53 - 9121 of 9137 Edit
0 3 0
Back to capita hey anyone else heard possible interest again from CVC ?, showed interest year before last at 32p so more of a bargain now - looks like debt being paid down, solid £4bn worth of contracts, might be worth a punt

[silly billy] 10/5/2022 18:21

Our target here is 0.05p.

Hope this helps.

[jonah292] 10/5/2022 08:59

More good news, surely share price will start moving up once the Malta factory opens in June and there's somewhere to produce the products on scale

[looneytune] 10/5/2022 06:48

Indeed. Here’s the official:
Patent granted for CannEpil®
Drug Delivery System
10 May 2022 ASX Code: MXC LSE Code: MXC
•
• • • •
by European IP Office
Key Highlights:
Patent granted by the Slovenian Intellectual Property Office for CannEpil® drug delivery carrier
of self-nanoemulsifying drug delivery system (SNEDDS) in Ionic Complex Concentrate
(CannEpil®-IL) for MGC Pharma’s phytocannabinoid-derived Investigational Medicinal Product
drug, which is designed to treat drug-resistant (refractory) epilepsy with a high CBD, low THC
formula.
CannEpil® is one of four products approved for prescription under the Medical Cannabis
Access Programme by the Health Product Regulatory Authority in the Republic of Ireland.
Between 300 - 400 patients have been prescribed CannEpil® across Australia and Ireland on a
monthly basis for the past two years.
MGC Pharma have signed an agreement with leading specialty pharmacy supplier, Sciencus
Rare, for the distribution of CannEpil® and neurological treatment CogniCann®.
CannEpil®-IL Patent utilises Graft Polymer's proprietary GraftBioTM SNEDDS technology (Self-
Nano Emulsifying Drug Delivery System), a unique platform designed to deliver active
ingredients more effectively and in higher concentrations to cells, improving the
bioavailability and synergy of the natural active ingredients.
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development of phytomedicines is pleased to announce that the Slovenian Intellectual Product Office has granted a patent for the Company’s Drug Delivery System of self-nanoemulsifying drug delivery system (SNEDDS) in Ionic Complex Concentrate (CannEpil®-IL).
The Patent
The Patent sets out the formulation of the Self-nanoemulsifying Cannabinoids-Ionic Complex concentrate drug delivery system, the method of manufacture, and its capacity for enhancing stability, solubility, and bioavailability of drugs designed for multiple neurological therapeutic applications.
The SNEDDS is based on the IV type (oil-free) nanotechnology which guarantees a globular molecule size below 50 nanometres (nm), in order to pass through the Blood Brain Barrier. For the effective treatment of neurological diseases, molecules must be less than 25nm, therefore the Self- nanoemulsifying Cannabinoids-Ionic Complex concentrate is based on an “Ionic Complex” that greatly increases solubility and bioavailability of the Active Pharmaceutical Ingredient, reducing the diameter of the molecule.
The grant of the Patent provides MGC Pharma commercial protection over the intellectual property associated with CannEpil®-IL, including its unique formulation and manufacturing process for 20 years.
The CannEpil® formulation is designed to treat Drug Resistant Epilepsy with a high CBD, low THC formulationandincorporatesGraftPolymer'sGraftBioTM self-nanoemulsifyingdrugdeliverysystem.
1 - 3

CannEpil®
CannEpil® is designed to treat one of the most common serious neurological conditions, Epilepsy, which affects approximately 600,000 people in the UK, and ~50 million people worldwide,1 with approximately 33% of those adults, and 20-25% of those children, suffering from Refractory Epilepsy (or Drug Resistant Epilepsy) which cannot be controlled with traditional anti-seizure medication.2 The annual cost for patients with epilepsy in the United States is estimated to be approximately 12.5 billion dollars.3
In 2019 CannEpil® was made available for distribution and prescription in Ireland under full governmental health insurance coverage, making it the second product available with coverage in the Republic of Ireland as part of Ireland’s Medical Cannabis Access Programme. There are over 37,000 people living with Epilepsy in Ireland alone, with CannEpil providing a solution to a significant number of those cases. 4 Between 300 - 400 patients have been prescribed CannEpil® across Australia and the Republic of Ireland monthly over the past two years.
CannEpil® is currently undergoing a randomised controlled trial investigating the effect of high CBD/low THC on driving performance, sedation and mood, in partnership with the Swinburne University of Technology in Australia (SUT). In addition to this, MGC Pharma are awaiting the approval of the import permits for CannEpil® by the Israel Ministry of Health in order to commence the Phase IIb trials for the formulation, as the Company looks to achieve Central Market Authorisation in the next 2-3 years.
Sciencus Rare Distribution
MGC Pharma has signed an agreement with leading European pharmacy supplier, Sciencus Rare for the distribution of MGC Pharma’s CannEpil® and CogniCann® products (announced 5th April 2022). With a turnover of £1.9 billion, Sciencus Rare is the largest distributor of specialised healthcare solutions for patients with long-term conditions, rare and ultra- rare diseases, spanning 50 different products and partnered with 40 pharmaceutical companies to deliver over 1.2 million orders around the world.
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “We are very pleased that the Patent for our proprietary drug delivery system has now been granted by the Slovenian Intellectual Property Office. This is a recognition of the strength of our product and provides legal commercial protection for our Company and our partner’s IP.
We are continuing to consistently build on the foundations that we have established in bringing our products to the central market and are proud of the progress we have made thus far. The grant of this Patent advances our European focus and affirms our commitment to treating patients with serious conditions on a global scale.”
--Ends—
Authorised for release by the Managing Director, for further information please contact:
MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director [phone] [e-mail]
UK Broker – Turner Pope
Andy Thacker
[phone] [e-mail]
MGC Pharmaceuticals Ltd
David Lim
Company Secretary
[phone] [e-mail]
UK PR Advisors – Tavistock
Charles Vivian / Tim Pearson [phone] [e-mail]
1 Source:
2 Source:
3 Source:
4 Source: study#:~:text=The%20study%20revealed%20that%20there,this%20number%20may%20be%20increasing.
2 - 3

About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.
Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU- GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels
3 - 3

[livewireplus] 10/5/2022 06:47

RNS out for CannEpil Drug Delivery System Patent Approval ....

[heatseek77] 10/5/2022 06:13

Profiles??

Anyway back to MGC related

hxxps://amp-theguardian-com.cdn.ampproject.org/c/s/amp.theguardian.com/society/2022/may/09/inside-one-of-the-first-licensed-medical-cannabis-labs-in-britain

[heatseek77] 10/5/2022 06:12

10,000 who's that?

[heatseek77] 10/5/2022 06:10

Sloppy here he goes sure sure sure 🥚🤦😂🤣

[sloppyjoe2] 09/5/2022 20:05

He buys£10k of shares? Not exactly a vote of confidence, is it? I've spent nearly that much...

[looneytune] 09/5/2022 17:51

Roby Zomer CEO buying shares in MGC
Some will say it’s not enough some will think it’s positive.

09/05/2022 6:13pm
UK Regulatory (RNS & others)

TIDMMXC

RNS Number : 7981K

MGC Pharmaceuticals Limited

09 May 2022

MGC Pharmaceuticals Ltd.

PDMR Notifications

09 May 2022

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, wishes to advise that the following Person Discharging Managerial Responsibilities ( PDMR ), Roby Zomer, Managing Director and CEO of MGC Pharma, has acquired shares in MGC Pharma on market, details of which are set out below.



1 Details of the person discharging managerial responsibilities/person
closely associated
(a) Name Roby Zomer
2 Reason for the notification
(a) Position Managing Director/CEO
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
Full name of entity MGC Pharmaceuticals Limited
Legal Entity Identifier 213800HRE3FQJ6RK4H10
Code
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; (iv) each place where transactions
have been conducted
(a) Description of the financial Fully Paid Ordinary Shares (DI)
instrument, type of
instrument
(b) Identification Code AU000000MXC6
(ISIN)
(c) Nature of transaction On-market purchase
(d) Currency Price Volume Total
GBP GBP0.013 819,672 GBP10,578
Aggregated information
GBP GBP0.013 819,672 GBP10,578
(e) Date of transaction 2022-05-06
(f) Place of transaction London Stock Exchange

[looneytune] 05/5/2022 10:27

The pondlife scumbags on the other thread should all be imprisoned for slander!

[heatseek77] 05/5/2022 10:24

See Vaston called Belnd out,he's right he is disgruntled 👍😂

[looneytune] 05/5/2022 10:23

The start of director purchases?

05/05/2022 11:10am
UK Regulatory (RNS & others)

TIDMMXC

RNS Number : 4714K

MGC Pharmaceuticals Limited

05 May 2022

MGC Pharmaceuticals Ltd.

PDMR Notifications

05 May 2022

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, wishes to advise that the following Person Discharging Managerial Responsibilities (PDMR), Dr Stephen Parker, a non-executive director of the Company, has acquired shares in MGC Pharma on market.